HALOPERIDOL showed no clear difference in adverse effects: specific ‐ dystonia compared with OTHER ANTIPSYCHOTIC: c. DROPERIDOL (moderate certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ tachycardia compared with OTHER ANTIPSYCHOTIC: i. THIOTHIXENE (very low certainty).
HALOPERIDOL may leads to higher adverse effects: specific ‐ acute dystonia compared with COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE (low certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ tremor by 7 days compared with OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE (very low certainty).
HALOPERIDOL showed no clear difference in adverse effects: Specific ‐ EPS during 24 hours compared with OTHER ANTIPSYCHOTIC: h. RISPERIDONE (low certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia during 24 hours compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia within 24 hours compared with PLACEBO/NIL (very low certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia during 72 hours compared with OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ cardiovascular ‐ hypotension compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ acute dystonia during 24 hours compared with OTHER ANTIPSYCHOTIC: h. RISPERIDONE (very low certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ central nervous system ‐ seizures compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia between 0‐3 days (IM phase) compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ rigidity between 0‐3 days (IM phase) compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects: any serious, specific ‐ dystonia during 24 hours compared with OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE (very low certainty).
HALOPERIDOL showed no clear difference in adverse effects ‐ general ‐ one or more drug‐related adverse effect compared with BENZODIAZEPINE: c. MIDAZOLAM (low certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ clinically significant abnormal ECG… compared with OTHER ANTIPSYCHOTIC: j. ZIPRASIDONE (very low certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia (only reported if occurred in… compared with COMBINATIONS: b. HALOPERIDOL + LORAZEPAM (very low certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ dystonia (only reported if occurred in… compared with BENZODIAZEPINE: b. LORAZEPAM (very low certainty).